In 2014, the National Institutes of Health, the Foundation for the NIH, the U.S. Food and Drug Administration, pharmaceutical companies, and nonprofit organizations created the Accelerating Medicines Partnership® (AMP®).
NIAMS participates in three AMP programs. Two of these are designed to accelerate the development of therapies for autoimmune diseases. One focuses on gene therapies for rare diseases. More information about these programs is below.
AMP Autoimmune and Immune-Mediated Diseases (AMP AIM) program (launched in 2021)
This program broadens and builds upon the earlier AMP RA/SLE program, described below. AMP AIM investigators characterize the cellular interactions and biological pathways that cause inflammation, injury, abnormal function, and clinical disease in rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and Sjögren’s disease.
AMP Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) program (actively funded 2014-2022)
AMP RA/SLE investigators examine the cell types, gene expression patterns, and signaling molecules that play a role in rheumatoid arthritis (RA) and/or systemic lupus erythematosus (SLE).
Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC)
The BGTC is establishing platforms and standards to speed the development and delivery of customized or “bespoke” gene therapies that could treat millions of people affected by rare diseases, including diseases too rare to be of commercial interest. The National Center for Advancing Translational Sciences is spearheading the effort at NIH.
Accelerating Medicines Partnership and AMP are registered service marks of the U.S. Department of Health and Human Services.